TraceLink grows market position in DACH region by 215%
Customers cite network connectivity, efficiency of partner onboarding, and seamless data exchange as significant differentiators.
TraceLink has announced 215% customer growth in the DACH region (Germany, Austria and Switzerland) for 2017.
Now serving over 40 customers in the region, TraceLink experienced a 138% growth in revenues from its German, Austrian and Swiss customers in 2017. To meet demand for its expanding DACH customer base, TraceLink has grown its European team by 169%, currently employing 22 native German-speaking team members.
To counter the threat of falsified medicines entering the legal supply chain, companies who manufacture, sell or dispense medications in the European Union must comply with track and trace regulations outlined in the Falsified Medicines Directive (FMD), including serialization, compliance reporting and verification requirements, by February 2019. Characterized by a strong community of small- and mid-sized life sciences organizations, in addition to several domestic large pharmaceutical companies, the DACH region represents a core area in the European market with a significant need for serialization and compliance with the EU FMD.
What DACH Customers and Partners Are Saying
Ortwin Kottwitz, CEO of Germany-based biotech and TraceLink customer, biosyn said: “We have customers and partners located all over the world and could not afford to lose time and resources by establishing individual point-to-point connections. After a thorough evaluation of solution providers, it was clear that TraceLink’s network approach would deliver the scalability we needed while providing a simple and fast connection into the EU Hub.”
Michael Unbehaun, manager engineering projects at R-Pharm Germany, a TraceLink partner, explained: “As a contract manufacturer, we need to be able to connect to multiple customers, managing and sharing data securely and efficiently. By accessing the TraceLink Life Sciences Cloud we can facilitate EU FMD compliance for our customers who supply markets in Europe. The simplicity of the solution, together with our proactive approach, has helped our customers achieve compliance ahead of the regulatory deadline.”
Boris Brunow of Switzerland-based contract packaging organization (CPO) Allpack, a TraceLink customer, said: “Our partnership with TraceLink has allowed us to manage and exchange serialization data more efficiently by eliminating outdated data transfer processes and simplifying the onboarding process for our customers. We evaluated potential partners over a 2-year period, eventually selecting TraceLink for its network approach, as well as its specialist focus in the pharma sector.”
“The EU FMD deadline is now less than a year away, requiring businesses to begin actively preparing for their serialization and regulatory requirements now. Over 190 companies are already serializing with TraceLink and with more than 265,000 partners on our network, we are well positioned to serve the growing number of companies of all sizes in Germany, Austria and Switzerland,” said Shabbir Dahod, president and CEO, TraceLink. “On an organizational level, we now have more employees dedicated to serving the DACH region than some of our competitors have for total number of employees, giving TraceLink a distinct advantage in our ability to service the specific needs of pharmaceutical and contract manufacturers across the region.”
To support companies’ compliance and serialization challenges in both the DACH region and across Europe, TraceLink is hosting FutureLink in Munich from 5–7 June 2018. FutureLink is the industry’s largest annual gathering of commercial and operational executives from the pharmaceutical and healthcare industries. The conference provides distinct learning forums for a range of business leaders to develop strategies that address rapidly approaching compliance deadlines — and to discuss the analog-to-digital information-sharing transformation taking place in the pharmaceutical and healthcare industries.
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance